Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax can move forward with a trial ... Meanwhile, Moderna said last week that it plans to file for FDA approval of its own combo vaccine by the end of the year. Write to Ben Glickman at ben ...

Novavax (NVX-CoV2373) is a brand-name vaccine that’s prescribed to help ... Note: After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews the side effects of the ...

The divestiture of the Czech facility follows U.S.-based Novavax's licensing deal worth at least $1.2 billion with French ...

It was later granted full FDA approval in August 2021 for people ... or nausea throughout the rest of the body. Novavax: The Novavax was the fourth COVID vaccine to be administered in the U.S ...

Novavax's COVID-19 vaccine won FDA approval in October 2023. It's different from the mRNA vaccines developed by Pfizer Inc. (PFE) and German partner BioNTech SE (BNTX) and by Moderna Inc. (MRNA ...

Novavax said the Food and ... COVID-19-flu and standalone flu vaccines. The company explained that the U.S. Food and Drug Administration (FDA) removed its clinical hold on the studies, and will ...